Denis Moro-Sibilot
Grenoble - CHU · University Hospital, Grenoble · Intergroupe Francophone de Cancerologie Thoracique
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Denis Moro-Sibilot as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:23 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04621188 · Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)Intergroupe Francophone de Cancerologie Thoracique · active not recruiting · Non Small Cell Lung Cancer Metastatic · study chair
- Ph2NCT04111705 · Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung CancerIntergroupe Francophone de Cancerologie Thoracique · completed · Non Small Cell Lung Cancer Metastatic · study chair
- N/ANCT03419286 · Transformation Into Small Cell Lung Cancer : a Mode of Resistance to TreatmentUniversity Hospital, Grenoble · completed · Small Cell Lung Cancer · principal investigator
- N/ANCT02727335 · Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK RearrangementsIntergroupe Francophone de Cancerologie Thoracique · completed · Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase Gene Mutation · principal investigator
- Ph3NCT00535275 · NSCLC Relapse Therapy After Surgery and Peri-operative ChemotherapyIntergroupe Francophone de Cancerologie Thoracique · terminated · Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph2NCT00198393 · Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IVIntergroupe Francophone de Cancerologie Thoracique · completed · Carcinoma, Non-Small-Cell Lung · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:23 UTC. The ranking covers the 200 most relevant of 66 PubMed records, and a shared surname and initials can bring in a namesake. All 66 on PubMed
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.N Engl J Med · 20183,177 citationsRCR 109.0
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med · 20132,837 citationsRCR 78.7
- 950 citationsRCR 30.0
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.Lancet Respir Med · 2019824 citationsRCR 28.8
- 762 citationsRCR 25.8
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.J Clin Oncol · 2016512 citationsRCR 16.3
- 508 citationsRCR 16.5
- Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.J Clin Oncol · 2002469 citationsRCR 10.4
- 432 citationsRCR 9.7
- 390 citationsRCR 14.0